chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left side of my mouse Lost any taste feelings, Left side of my face got swollen, my left eye doesn't close, my mouse was dreapping down, difficulty to talk. 10/24/2019 my symptoms started one by one and 10/28 I went to ER 09/17/2019 I did flu shot in my local pharmacy. First week after shot I was feeling seek - weakness, throat was screeching. ER told me my diagnose - Bell's palsy. Curently I'm under care of my doctor. I did flu shot on 09/17/2019. First week I was filling seek. My symptoms as left eye doesn't close, difficulty to talk started since 10/24/19 one by one. On 10/28 I went to ER and they told me my diagnose - Bell's palsy.
Patient was given the 2nd dose of the Moderna vaccine on day 21 vs day 28. She did not have symptoms except sore arm.
UrticariaPruritus developed shingles Narrative:  Patient began feeling itchy on Sunday, 11/14/21 and rash started Monday, 11/15/21. Determined to be shingles
Initial report received from a healthcare professional on 21 May 2013. A 41-year-old female patient had received a booster dose of ADACEL vaccine (lot number: unknown, route and site of administration unknown) on 21 March 2013. The patient illness at time of vaccination was reported as unknown. Patient's pre-existing physician diagnosed allergies, birth defects, medical conditions and concomitant medications were unknown. It was reported that few weeks after vaccination patient experienced cough on an unspecified date. On 10 May 2013, Laboratory investigations from "Bordetella pertussis labs" included: IGA was 41, igGA was elevated at 41, PTI iGA was at 41, fHigG was 88 and pTigG was at 87. Corrective treatment was not reported. At the time of this report, the outcome of the event was unknown. List of document held by sender: None.
Patient was being walked to the restroom when she said she felt like she was going to pass out. Healthcare professional was able to get her to the nearest exam room and the patient collapsed in their arms.
Patient received vaccination in Right arm and sat for observation. Patient reported difficulty breathing and numbness in her throat. Pharmacist administered 10ml of liquid Diphenydramine and called paramedics. Paramedics arrived in 15-20 minutes, but did not feel patient should be admitted as the symptoms were resolving.
52-year-old male reports developing multiple HSV simplex lesions around his upper lips within 24 hours of receiving the second Covid 19 vaccine.  Patient has had HSV-1 lesions before but never to this extent; patient is otherwise stable and afebrile.  He has no radicular pain. Labs are ordered for CBC and a CMP. The vaccine support center was called at approximately 3:35 PM and message left.  The vaccine support center was called again on February 26, 2021 at approximately 9:20 AM. Provider spoke with NP for consultation. VAERS CDC report advised. No further action required. Antiviral medication was not offered due to the fact that patient was on day 6 post outbreak and out of the window of opportunity to treat acutely.
Extreme fatigue, felt very warm all over body for 14 - 16 hours, exceptional pruritus on head and back, all joints are exceptionally achey
Nov 3rd got flu shot and needle insertion didn't hurt, but "it felt like the needle hit something". Reports he had a "fireball" of pain when medicine injected. For 2 hours pain at injection site #5-6 then decreased #2 until Nov 29, 2008 when pain went up to 8-9 and he could "hardly move his arm".
Information has been received from a physician concerning a 1 year old female who on 27-FEB-2006 was vaccinated SC with a 0.5 mL dose of measles virus vaccine (+) mumps virus vaccine live (+) rubella virus vaccine live. On 08-MAR-2006 the patient was evaluated by the physician due to a macular rash on chest and abdomen and low grade fever. Subsequently, the patient recovered on an unspecified date. There was no product quality complaint involved. Additional information has been requested.
Information has been received from a physician concerning a 4 year old male who on 1/17/02 was vaccinated with a dose of MMR (lot 632343/1080J). Concomitant therapy included a first, second, and third dose of hepatitis B virus vaccine on 1/19/99 (lot 626441/0600H), 3/9/99 (lot 626441/0600H), and 10/27/99 (lot 632558/1180J), respectively. Subsequently, as reported on 9/22/03, the patient was recently diagnosed with sensory motor dysfunction integration disorder and had high levels of mercury in his blood. Medical attention was sought. Upon internal review, sensory motor dysfunction integration disorder was determined to be an other important medical event (OMIC). Additional information has been requested.
Fatigue; Body Aches/Soreness; Feverish; This is a spontaneous report from a contactable consumer or other non hcp. A 45-years-old non pregnancy female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/lot number: EM9810) via an unspecified route of administration in Arm Left on 09Feb2021 18:45 (age at vaccination 45years old, Pregnant at Time of Vaccination: No) as single dose for covid-19 immunisation. Medical history included anxiety from an unknown date and unknown if ongoing other medical history: anxiety/MDD (past), major depression from an unknown date and unknown if ongoing other medical history, food allergy from an unknown date and unknown if ongoing known allergies: valium, high intolerance to shellfish, covid-19 from an unknown date and unknown if ongoing. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medication(s) included levonorgestrel (MIRENA) taken for an unspecified indication, start and stop date were not reported. The patient previously took valium and experienced drug hypersensitivity. Since the vaccination, the patient had not been tested positive for COVID-19. On 10Feb2021 18:45 the patient experienced fatigue, body aches/soreness, feverish. The patient did not receive any treatment for the adverse events. The clinical outcome of the event was recovered.  No follow-up attempts are needed. No further information is expected.
Mild fever. Extreme muscle pain all over the body and at joints. Headache. Symptoms start after 12 hours of vaccination and started to recover after 18 hours. All described symptoms above generally disappear after 24 hours, but occasional muscle pain at places with injury history persists, including the place where the bivalent vaccine was injected.  Also, new pains from the upper portion of the spine start.  The left hand on the vaccinated arm occasionally feels numb. No treatment except drinking water was given during the whole process.
The report is due to an extra dose given to patient. Patient had the primary series and the Bivalent dose. Bivalent was given 10/6/22. Another dose of primary series was given today. There was no adverse reaction at this time. Patient is being monitored.
seizures / prolonged seizures; This case was reported by a other health professional via other manufacturer and described the occurrence of prolonged seizure in a child patient who received DTPa (DTaP vaccine) for prophylaxis.   On an unknown date, the patient received DTaP vaccine at an unknown dose. On an unknown date, less than a week after receiving DTaP vaccine, the patient experienced prolonged seizure (serious criteria GSK medically significant). On an unknown date, the outcome of the prolonged seizure was unknown.   It was unknown if the reporter considered the prolonged seizure to be related to DTaP vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The reporter did not have brand name of DTap vaccine. Within 7 days after immunization, the patient experienced prolonged seizures.
Patient received Pnuemovax-23 around 6:45pm at pharmacy - she called pharmacy in morning saying that her arm was very swollen and red on the inside of her elbow.  I talked to her and asked if this was near the injection site and she said that it was further down and on the inside of her arm.  Later in the day we got a prescription for antibiotic from her PCP.  Her husband (a healthcare provider) came in and said that the antibiotic was precautionary in case it continued to spread and/or infection occurred.   Currently treating with hot/cold and benadryl.
approx 2yrs p/vax pt exp breakthrough varicella w/approx 15 lesions.
Proquad administered to patient which was above recommended age.  No adverse effects.   No recommendations to revaccinate.
Chronic hives were in remission since June. About 24 hours after flu + covid booster hives returned aggressively
Reaction to covid-19 vaccine; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Reaction to covid-19 vaccine) and FATIGUE (Tiredness) in an adult male patient who received mRNA-1273 (COVID 19 Vaccine Moderna) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 18-Aug-2018, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram every two weeks. In May 2021, the patient received first dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) 1 dosage form. In June 2021, received second dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) dosage was changed to 1 dosage form. In February 2022, received third dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) dosage was changed to 1 dosage form. In June 2022, received fourth dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) dosage was changed to 1 dosage form. In June 2022, the patient experienced IMMUNISATION REACTION (Reaction to covid-19 vaccine) and FATIGUE (Tiredness). At the time of the report, IMMUNISATION REACTION (Reaction to covid-19 vaccine) outcome was unknown and FATIGUE (Tiredness) had not resolved.            Concomitant product use was not provided by the reporter. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Primary reporter did not have the lot number information, because the packaging was discarded. The reporter's causality for the event of tiredness with humira 40mg/0.8ml(adalimumab) was no reasonable possibility. Treatment information was not provided.   This case was linked to MOD-2022-636537.
Unexpected chest pain along the left side, especially painful the first night. Light pain lasting 10-15 minutes randomly usually once per day on days following date of vaccination. Patient states that it did not feel like heartburn. Patient has never had a heart attack and cannot compare the two experiences.  Expected right arm pain at injection site that subsided after a day or two.
Information has been received from 2 healthcare workers referring to a patient of unknown age and gender. The patient's medical history was not reported. On 22-MAY-2015, the patient was received improperly stored VARIVAX (Merck) (lot # K026385, exp date 15-DEC-2016, dose and route unknown). Concomitant medication was not reported. No adverse effects were reported. No product quality issue (PQC) was involved. This is one of several reports received from the same source. Additional information is not expected since the reporter don't wish us to contact.
her legs got weak; she almost couldn't get up on the bus; it took her energy away; her arm started hurting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient received BNT162b2 (BNT162B2), on 03Mar2021 as dose 1, single (Batch/Lot number: unknown) at the age of 60 years for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (ongoing); "Pulmonary hypertension" (ongoing), notes: She was on a high dose steroid for her Pulmonary Hypertension; "Arthritis" (ongoing); "Overweight" (ongoing), notes: A little Overweight; "Hemolytic anemia" (ongoing); "Migraine" (ongoing); "Pacemaker" (ongoing); "Oxygen 24 Hours" (ongoing); "Massive Blood Clots" (ongoing); "Compromised Immune System" (ongoing); "Heart and Lung Disease" (ongoing); "Lung Disease" (ongoing); "Lupus" (ongoing); "Macrocytic cells" (unspecified if ongoing), notes: she has Macrocytic cells because they are so large. The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 04Mar2021, outcome "unknown", described as "her arm started hurting"; MUSCULAR WEAKNESS (non-serious) with onset 04Mar2021, outcome "unknown", described as "her legs got weak"; ASTHENIA (non-serious) with onset 04Mar2021, outcome "unknown", described as "it took her energy away"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 04Mar2021, outcome "unknown", described as "she almost couldn't get up on the bus". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: It was reported that, Patient was trying to lose weight. She was on a high dose steroid for her Pulmonary Hypertension because it was really bad and the high dose steroids caused her to gain weight. She tries to take care of herself. Patient stated she has a pacemaker, she was on 24 hour oxygen, she is on coumadin because she has massive blood clots, her Immune System is Compromised, Heart and Lung Disease, Diabetes, Pulmonary Hypertension, Lupus, Arthritis and she was told she is a little overweight. She also has Migraines. Investigations included, they are always drawing PT/INR tests and running other tests such as CBC because her Red Blood Cells are too big. She had Hemolytic Anemia. States she has Macrocytic cells because they are so large. If her Hemoglobin and Hematocrit drop, she has to go back to the Cancer Doctor again. Patient stated with the First One, her arm started hurting the next day and her legs got weak and she almost couldn't get up on the bus. The social worker said she needed to use a wheelchair for a while because it took her energy away.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information on patient's pertinent medical history and concurrent condition was not reported. The medical assistant reported that on 19-DEC-2016, a patient was vaccinated with VAQTA lot # L036300 (route and dose not reported) and later discovered that the product had expired on 04-NOV-2016. No adverse effect was reported in the patient. No other information was available. Additional information has been requested.
About a week after my vaccine, I felt tiredness and was having trouble sleeping. I got COVID-19 symptoms on 12/27/2021- symptoms of backache and tiredness. I had a fever of 101. I had a positive COVID-19 test on 12/28/2021 at a clinic. These symptoms lasted 24 hours. I had a thumping in both ears 3 days later. It would happen mostly at night and periodically that went away after 2 months. I still have symptoms of lightheadedness that my doctor said was due to long term COVID. I also had pain in my neck and shoulder that still hurts today. I had Carotid artery test, blood work, and a calcium score test that came back negative.
Starting at about 4 hours after the shot had a headache.  At 6 hours after mild fever began and severe body ache and eyes very dry and red.  At around 7 hours began to have sore throat which was not listed under symptom.  Tingling in nose as if I have to sneeze but am unable.  Very tired and irritable.  Today is the next day and I feel all these symptoms at once.  It is nearly as bad as actually having the flu.  Not recovered yet but I suspect I will. Don't know who manufactured it but I had to enter something or I couldn't complete the form.
Patient presented with severe epigastric pain the day after vaccine. Found to have acute pancreatitis on CT scan (not due to biliary obstruction as labs normal, denies history of alcohol use, IgG4 negative). Has since decompensated requiring intubation, vent support, maximum use of four pressers, CVVH initiation for acidosis and fluid overload, bicarb drip, and  calcium drip.
This spontaneous report was received from a licensed practical nurse regarding unspecified patients of unknown age and gender. The patients' pertinent medical histories, drug reactions or allergies and concomitant therapies were not reported. On unspecified dates, the patients were vaccinated with improperly stored PNEUMOVAX 23 (lot # M032635 with expiry date 05-MAY-2018 and lot# M035104 with expiry date 06-MAY-2016) (dosing details unknown). The administered dose experienced a temperature excursion of 60.1 Fahrenheit(F) for 14 hours and 15 minutes, 47.5 Fahrenheit(F) for 30 minutes, 47.3 Fahrenheit(F) for 30 minutes, 50.7 Fahrenheit(F) for 30 minutes and 32.7 Fahrenheit(F) for 2 hours and 15 minutes. There was no previous temperature excursion. The call was because of a data logger. No symptoms were reported. This is one of the two reports received from the same reporter. Additional information has been requested.
This case was reported by a nurse and described the occurrence of worsened arm arthralgia in a 81-year-old male subject who was vaccinated with influenza virus vaccine (Fluarix) for prophylaxis.  The subject's medical history included arm arthralgia prior to receiving the vaccination with Fluarix. His allergies included penicillin, terazosin (Hytrin), clopidogrel (Plavix), hydrochlorothiazide and possibly prednisolone, dexamethasone 9Decadron) and methylprednisone (Depo Medrol).  Concurrent mediations included Aspirin and cholestyramine (Questran lite). The subject had not experienced any reactions after vaccination with previous influenza virus vaccines.  On 11 November 2005, the subject received an unspecified dose of Fluarix (0.5 ml, intramuscular, left arm).  The lot number was ASLUA141BA and the expiration date was 26 July 2006.  At an unspecified time after vaccination with Fluarix, the subject experienced worsened arm arthralgia, which required medical attention at his doctor's office.  At the time of reporting the outcome of the event was worse. Follow-up information on 26 September 2006 indicated that the subject's condition was still not resolved. The subject's physician felt that the event could possibly be related to treatment with FLUARIX.
a patient was administered a dose of improperly stored VARIVAX; The patient experienced no symptoms; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug allergies/reactions and concomitant medications were not provided.  On 24-APR-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (dosage regimen was not provided), lot# S028920, expiration date 16-SEP-2021, administered subcutaneously, as prophylaxis. Varicella virus vaccine live (Oka/Merck) (VARIVAX) was reconstituted with properly stored sterile diluent (MERCK STERILE DILUENT).  The improperly stored of varicella virus vaccine live (Oka/Merck) (VARIVAX) experienced a temperature of -8.1 degree Celsius (C) for 1 hours and 30 minutes; without a previous temperature excursion and was called because of a digital data logger. The patient experienced no symptoms. No further information was provided.
got 0.7 ml not 0.5 ml; This spontaneous case was reported by a consumer and describes the occurrence of ACCIDENTAL OVERDOSE (got 0.7 ml not 0.5 ml) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .7 ml. On an unknown date, the patient experienced ACCIDENTAL OVERDOSE (got 0.7 ml not 0.5 ml). At the time of the report, ACCIDENTAL OVERDOSE (got 0.7 ml not 0.5 ml) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No information about concomitant medications was provided.
pt devel a rash on face,arms,trunk et legs 11 days p/vax;low grade fever noted;had altered sleeping 12hrs a/onset of rash;no other s/s noted;good appetite;nl behavior;24JUL95 tc rash lasted 1 1/2 days no other s/sx noted
episodes of severe dyspnea and lightheadedness over the past couple of weeks; episodes of severe dyspnea and lightheadedness over the past couple of weeks; ventricular tachycardia with a rate of 270; severe right ventricular dilatation and dysfunction with inflammation and fibrosis throughout the RV and septum, but minimal LV involvement.; severe right ventricular dilatation and dysfunction with inflammation and fibrosis throughout the RV and septum, but minimal LV involvement.; severe right ventricular dilatation and dysfunction with inflammation and fibrosis throughout the RV and septum, but minimal LV involvement.; This is a spontaneous report from a contactable physician (patient). A 4-decade-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via unspecified route of administration on 18Dec2020 at single dose for COVID-19 immunization. Patient medical history and concomitant medications were not reported. Patient reported that on 18Dec2020, she received the first dose of Pfizer / BioNTech vaccine. On 30Dec2020 (Wednesday), she was diagnosed of ventricular tachycardia with a rate of 270, severe right ventricular dilatation and dysfunction with inflammation and fibrosis throughout the RV and septum, but minimal LV involvement. On 30Dec2020, EKG showing RBBB with PR 234 (in presence of normal EKG and ECHO from Dec2016), and positive troponin 0.07 that has remained stable in the following week. On unspecified date in Jan2021, the patient had been having episodes of severe dyspnea and lightheadedness over the past couple of weeks, but it had been sporadic - it became significantly worse in the last 2 weeks, which is why patient sought out an electrophysiologist (and purchased at-home EKG monitor on which she saw the VT). Patient do not know the cause at all. She was tested for SARS-CoV-2 antibody yesterday (unspecified date in Jan2021), which was negative. Patient was also trying to determine if she should get the second dose or not. She will have cardiac PET scan next week, which hopefully further elucidate causes. Outcome of the events dyspnea and lightheadedness was not recovered; while outcome of other events was unknown.  Information on the Lot/Batch number has been requested.; Sender's Comments: Based on the available information, a causal relationship between reported events and BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Felt like she was going to faint-Medium, Systemic: Nausea-Medium